Rheumatoid Arthritis Drugs Market Growth Outlook Through 2024-2033

Overview and Scope
Rheumatoid arthritis drugs refer to drugs given for the treatment of an autoimmune disease, which has symptoms like inflammation of the tissues around the joints. These medications minimize permanent harm to the joints and other tissues while slowing the progression of rheumatoid arthritis.

Sizing and Forecast
The rheumatoid arthritis drugs market size has grown marginally in recent years. It will grow from $60.82 billion in 2023 to $61.06 billion in 2024 at a compound annual growth rate (CAGR) of 0.4%. The growth in the historic period can be attributed to increasing disease prevalence, healthcare infrastructure growth, awareness and education initiatives, government initiatives and support, strategic collaborations.

The rheumatoid arthritis drugs market size is expected to see marginal growth in the next few years. It will grow to $64.86 billion in 2028 at a compound annual growth rate (CAGR) of 1.5%. The growth in the forecast period can be attributed to personalized medicine trends, emerging markets growth, pipeline development, focus on combination therapies, increasing healthcare expenditure. Major trends in the forecast period include biological therapies dominance, biosimilars impact, personalized medicine advances, oral therapies growth, focus on early diagnosis and intervention.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Segmentation & Regional Insights
The rheumatoid arthritis drugs market covered in this report is segmented –

1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Response Modifiers (BRMs), Other Drug Types
2) By Route Of Administration: Oral, Parenteral, Topical, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

North America was the largest region in the rheumatoid arthritis drugs market in 2023. North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=10120&type=smp

Major Driver Impacting Market Growth
The growing cases of arthritis is expected to propel the growth of the rheumatoid arthritis drugs market going forward. Rheumatoid arthritis refers to an autoimmune and inflammatory condition where the immune system knowingly harms healthy cells in the body, leading to inflammation (painful swelling) in the body areas affected. Rheumatoid arthritis drugs and self-management techniques are readily available to treat RA effectively. The drugs reduce pain, enhance joint flexibility, and inhibit the spread of disease. For instance, in November 2021, according to the Centers for Disease Control and Prevention, a US-based health protection agency, 2021 highlights, in the United States, there were 54.4 million adult-aged people diagnosed with arthritis, which is projected to reach 78 million by the year 2040. Therefore, growing cases of arthritis is expected to drive the rheumatoid arthritis drug market.

Key Industry Players

Major companies operating in the rheumatoid arthritis drugs market report are Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck & Co Inc., Johnson & Johnson Inc., Bayer AG, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A, Biogen Inc., Regeneron Pharmaceuticals Inc., Galapagos NV, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, UCB S.A. Belgium., Astellas Pharma Inc., Corbus Pharmaceuticals Holdings Inc., Roche Holding AG, Daiichi Sankyo Company Limited, Chr. Hansen Holding A/S, Ipsen S.A, Mallinckrodt Pharmaceuticals, Gilead Sciences Inc.

The rheumatoid arthritis drugs market report table of contents includes:

1. Executive Summary
2. Rheumatoid Arthritis Drugs Market Characteristics
3. Rheumatoid Arthritis Drugs Market Trends And Strategies
4. Rheumatoid Arthritis Drugs Market – Macro Economic Scenario
5. Global Rheumatoid Arthritis Drugs Market Size and Growth
.
.
.
31. Global Rheumatoid Arthritis Drugs Market Competitive Benchmarking
32. Global Rheumatoid Arthritis Drugs Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Rheumatoid Arthritis Drugs Market
34. Rheumatoid Arthritis Drugs Market Future Outlook and Potential Analysis
35. Appendix

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model